Literature DB >> 4039764

Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.

M P Johnson, S A Thompson, D M Lubaroff.   

Abstract

Many investigators have reported effects of the pituitary hormone, prolactin, on the physiology and biochemistry of the rat prostate gland, particularly the lateral or dorsolateral lobe. The Dunning R3327H is a transplantable rat prostatic adenocarcinoma derived from a spontaneous tumor of the Copenhagen rat dorsolateral prostate. This study describes and compares morphological and physiological effects of prolactin on rat dorsolateral prostate and two sublines of the Dunning tumor. Ectopic pituitary grafts were used to induce chronic hyperprolactinemia in castrated rats receiving androgen supplement to provide a relatively controlled hormonal environment in which the effects of prolactin were maximally and consistently observed. Gravimetric and biochemical analyses, as well as ultrastructural study, provided evidence of prolactin's stimulatory effect on dorsolateral prostate growth and secretory activity. Hyperprolactinemia stimulated the growth of the well-differentiated, androgen-dependent R3327/3219 tumor subline with an increase in weight, volume and the total content of DNA, protein and zinc. There were no changes in tumor morphology. In contrast, the anaplastic androgen-independent R3327/150 tumor subline did not respond to graft-induced hyperprolactinemia. This differential response of the two R3327 tumor sublines attests to the complexity of prolactin's effects on prostatic tissue and to the extent of the deterioration of endocrine control that often accompanies tumor progression. Prolactin binding in the R3327 sublines was studied using immunohistochemical staining and radioligand assay, but produced complex results which raise questions about the discrepancy between hormone binding and biological action of prolactin in prostatic tissues.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039764     DOI: 10.1016/s0022-5347(17)49392-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions.

Authors:  I Leav; F B Merk; K F Lee; M Loda; M Mandoki; J E McNeal; S M Ho
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture.

Authors:  E Jimenez-Hakim; M el-Azouzi; P M Black
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

3.  Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Authors:  Leticia Oliveira-Ferrer; Jasmin Wellbrock; Udo Bartsch; Eva Maria Murga Penas; Jessica Hauschild; Marianne Klokow; Carsten Bokemeyer; Walter Fiedler; Gunter Schuch
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.